Medication info
Lyrica 75 mg (Pregabalin)

Lyrica 75 mg (Pregabalin)

Prescription medicationTabletOral
Ingredient · strength
Pregabalin›75mg / 1 tablet
Manufacturer / importer
Withus Pharmaceutical Co., Ltd.
Appearance
Pale green oval tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202002264 · Approved 2020.03.31 · Insurance code 660703410

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)
Who takes it
Adults · Children
Adult dose
This medicine, as pregabalin, is administered orally in 2 divided doses per day, with or without food. As this medicine is excreted mainly by the kidneys, the dosage should be adjusted in patients with impaired renal function. (Refer to “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment As the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) / 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the dosing regimen. b: A supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Withus Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of epilepsy (partial seizures)

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medicine is used for alleviating peripheral and central neuropathic pain in adults. It also serves as an adjunct treatment for partial seizures in epilepsy patients, with or without secondary general symptoms. Additionally, it helps relieve pain caused by fibromyalgia. In other words, this medication is used to treat various neurological disorders and pain conditions.

How to take

Adult dose

This medicine, as pregabalin, is administered orally in 2 divided doses per day, with or without food. As this medicine is excreted mainly by the kidneys, the dosage should be adjusted in patients with impaired renal function. (Refer to “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment As the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) / 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the dosing regimen. b: A supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts and behaviors, so you should consult your doctor immediately if you notice any changes in mood or behavior during treatment. Patients who are allergic to pregabalin or any components of this medication should not take it. Patients with diabetes may experience changes in blood sugar control due to weight gain, and adjustments in the dosage of diabetic medication may be needed. If you experience symptoms of angioedema, such as swelling of the face or around the mouth, stop taking the drug immediately and consult your healthcare provider. Elderly patients may experience increased dizziness or drowsiness, so special caution should be taken during initial treatment, and it is advisable to avoid driving or operating hazardous machinery. Some patients may experience blurred vision or vision changes; if these symptoms occur, the medication should be stopped or a doctor consulted. Discontinuation of medication may result in withdrawal symptoms such as insomnia, headache, and anxiety, so do not stop suddenly and consult your healthcare provider. As there is a risk of drug abuse, special caution should be exercised by patients with a history of substance abuse or mental illness, and any unusual behavior should be reported immediately. Patients with impaired renal function may need dose adjustments, so it should be taken according to a doctor's instructions. Patients with severe heart disease should be cautious as there is a risk of congestive heart failure. Care should be taken when combining this medication with opioid analgesics, as it may increase the risk of central nervous system depression. Patients with respiratory or neurological diseases or elderly patients may require dose adjustments due to the risk of severe respiratory depression. Pregnant women should not use this medication in the early stages of pregnancy as it may affect the fetus, and women of childbearing age should use effective contraception. While breastfeeding, this medication may be passed into breast milk, so it is advisable to discuss whether to discontinue breastfeeding or the medication with your doctor. This medication can cause dizziness and drowsiness, so you should check your condition before driving or operating hazardous machinery. Rarely, severe skin reactions may occur, so if you notice any unusual symptoms such as skin rash or swelling, stop taking the medication immediately and consult your healthcare provider. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and you should visit a medical institution immediately; treatment such as hemodialysis may be required if necessary. Special caution is needed for children, elderly patients, and those with impaired renal function in terms of storage and use, and it should be kept out of reach of children.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital edema
  • upper respiratory edema
  • dizziness
  • drowsiness
Show 204 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in eyesight
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • depression
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • weight gain
  • rhinitis
  • neutropenia
  • increased appetite
  • anorexia
  • hypoglycemia
  • confusion
  • disorientation
  • hypersensitivity
  • depression
  • relief
  • decreased libido
  • insomnia
  • depersonalization
  • sexual hyperesthesia
  • restlessness
  • anxiety
  • mood swings
  • decreased emotional state
  • elevated mood
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • abnormal motor coordination
  • balance disorder
  • amnesia
  • attention disorder
  • memory impairment
  • tremor
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • diminished reflexes
  • movement disorders
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • action tremor
  • syncope
  • confusion
  • hypokinesia
  • olfactory abnormalities
  • loss of taste
  • writing disorders
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eyes
  • ocular swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception
  • strabismus
  • visual brightness
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal bloating
  • constipation
  • dry mouth
  • abdominal distension
  • excessive salivation
  • gastroesophageal reflux
  • decreased oral sensation
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disturbances
  • incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • abnormal sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reaction
  • headache
  • loss of consciousness
  • mental disorders
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confusional state
  • depression
  • agitation
  • restlessness
  • seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is best to store it at room temperature between 1 degree and 30 degrees Celsius. By storing it this way, the efficacy of the medication can be maintained for a longer period.

Appearance and packaging

Appearance

Pale green oval tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.